HIV Type-1 Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Developing Therapies - ViiV Healthcare, GlaxoSmithKline, PPD, Merck, Gilead, Janssen, AbbVie, Sanofi

The HIV type-1 market is expected to grow by factors like an increase in the patient pool, rising healthcare spending across the globe, the expected entry of emerging therapies, and others.

New York, USA, Nov. 02, 2023 (GLOBE NEWSWIRE) -- *HIV Type-1 Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Developing Therapies - ViiV Healthcare, GlaxoSmithKline, PPD, Merck, Gilead, Janssen, AbbVie, Sanofi*

*The HIV type-1 market is expected to grow by factors like an increase in the patient pool, rising healthcare spending across the globe, the expected entry of emerging therapies, and others.*

DelveInsight’s *HIV Type-1 Market Insights* report includes a comprehensive understanding of current treatment practices, HIV type-1 emerging drugs, market share of individual therapies, and current and forecasted HIV type-1 market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

*Key Takeaways from the HIV Type-1 Market Report*

· As per DelveInsight’s analysis, the HIV type-1 market size was found to be *USD 22.6 billion* in 2020 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
· As per DelveInsight estimates, the diagnosed prevalent cases of HIV in the 7MM were found to be approximately *1.6 million* cases in 2022. These cases will increase in the study period (2019-2032).
· Leading HIV type-1 companies such as *MacroGenics, CytoDyn, Inc., ViiV Healthcare, GlaxoSmithKline, PPD, Excision BioTherapeutics, TaiMed Biologics Inc., Gilead Sciences, ST Pharm Co., Ltd., Merck Sharp & Dohme LLC, Janssen Sciences Ireland UC, Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), AbbVie, Sanofi, ModeX Therapeutics, *and others are developing novel HIV type-1 drugs that can be available in the HIV type-1 market in the coming years.
· Some of the key therapies for HIV type-1 treatment include *MGD020, PRO 140, DTG/3TC, EBT-101, 18F-Raltegravir, TMB-365/TMB-380, Doravirine, GS-5894, STP0404, MK-8591A, Etravirine, VIR-1388, VH3739937, CVC, SAR441236**, *and others. 

Discover which therapies are expected to grab the major HIV type-1 market share @ *HIV Type-1 Market Report*

*HIV Type-1 Overview*

Human Immunodeficiency Virus (HIV) is a pathogen that attacks immune system cells, rendering individuals more susceptible to infections and illnesses. Unlike conventional DNA-based viruses, HIV is a retrovirus composed of RNA. Its primary targets are immune cells, particularly those with CD4 receptors on their surfaces, such as T lymphocytes and white blood cells. There are two primary HIV types: HIV-1 and HIV-2, with HIV-1 being the most common, affecting more than 90% of HIV-positive individuals. HIV-1 can be further divided into subcategories: M, N, O, and P. Diagnosis methods encompass antibody tests, antigen/antibody tests, and Nucleic Acid Tests (NATs). During treatment, additional tests monitor viral load, CD4 count, and drug resistance.

*HIV Type-1 Epidemiology Segmentation*

The HIV type-1 epidemiology section provides insights into the historical and current HIV type-1 patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The *HIV type-1 market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

· Total Prevalent Cases of HIV
· Total Diagnosed Prevalent Cases of HIV
· Type-Specific Diagnosed Prevalent Cases of HIV
· Gender-Specific Diagnosed Prevalent Cases of HIV-1
· Diagnosed Prevalent Cases of HIV-1 By Route of Transmission
· Age-Specific Diagnosed Prevalent Cases of HIV-1 Scenario 

Download the report to understand which factors are driving HIV type-1 epidemiology trends @ *HIV Type-1 Epidemiological Insights*

*HIV Type-1 Treatment Market *

Numerous medications are accessible for managing HIV, organized into seven distinct drug classes. A drug class is a category of drugs that share similar characteristics, including their mode of action, chemical structure, and approved usage. Approved antiretroviral (ARV) medications for HIV treatment are categorized into the following classes, each targeting a different aspect of the HIV life cycle: *nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, and integrase strand transfer inhibitors (INSTIs)*. Notably, fusion inhibitors, CCR5 antagonists, and post-attachment inhibitors are often referred to as entry inhibitors because they hinder HIV from entering CD4 cells.

NNRTIs, such as *efavirenz (Sustiva), rilpivirine (Edurant), doravirine (Pifeltro)*, function by obstructing HIV's reverse transcriptase enzyme, vital for HIV replication. NRTIs, including *abacavir (Ziagen), tenofovir (Viread), emtricitabine (Emtriva), lamivudine (Epivir)*, mimic flawed building blocks that HIV relies on for copying itself. PIs act by disabling HIV protease, a crucial protein that HIV relies on for its replication. Some common examples of PIs include *atazanavir (Reyataz), darunavir (Prezista), and the combination lopinavir/ritonavir (Kaletra)*. CCR5 antagonists like *Selzentry/Celsentri* marked the pioneering class of antiretroviral medications designed to impact host cells rather than viral particles. Tograzo and Rukobia have received approval for the treatment of HIV-1 infection in adults with extensive treatment history, battling multidrug-resistant (MDR) HIV-1 strains while their current antiretroviral therapy proves ineffective.

Learn more about the FDA-approved drugs for HIV type-1 @ *Drugs for* *HIV Type-1 Treatment** *

*Key HIV Type-1 Therapies and Companies*

· MGD020: MacroGenics
· PRO 140: CytoDyn, Inc.
· DTG/3TC: ViiV Healthcare/GlaxoSmithKline/PPD
· EBT-101: Excision BioTherapeutics
· 18F-Raltegravir: Merck Sharp & Dohme LLC
· TMB-365/TMB-380: TaiMed Biologics Inc.
· Doravirine: Merck Sharp & Dohme LLC
· GS-5894: Gilead Sciences
· STP0404: ST Pharm Co., Ltd.
· MK-8591A: Merck Sharp & Dohme LLC
· Etravirine: Janssen Sciences Ireland UC
· VIR-1388: Vir Biotechnology, Inc./National Institute of Allergy and Infectious Diseases (NIAID)
· VH3739937: ViiV Healthcare
· CVC: AbbVie/National Institute of Allergy and Infectious Diseases (NIAID)
· SAR441236: Sanofi/ModeX Therapeutics

To know more about HIV type-1 clinical trials, visit @ *HIV Type-1 Treatment Drugs** *

*HIV Type-1 Market Dynamics*

The HIV type-1 market dynamics are anticipated to change in the coming years. The *prevalence of HIV *has increased due to a *growing population and a decline in HIV-related mortality rates*. There is also a *rising level of awareness* about the disease among both healthcare professionals and patients. To cater to the specific needs of various HIV-1 patient groups such as infants, young children, pregnant women, and the elderly, *more customized therapies* have been developed. HIV type-1 market players are responding to the increasing demand for treatments that offer *enhanced patient compliance*, reduced side effects, improved resistance profiles, and long-acting options.

However, several factors may impede the growth of the HIV type-1 market. *Insufficient resources* within rural communities contribute to delayed diagnoses, and the *presence of stigma and discrimination* further exacerbates the challenge of low treatment adherence and HIV diagnosis. These factors collectively hinder access to therapies and impede the growth of the HIV-1 market. Moreover, HIV type-1 treatment poses a *significant economic burden* and disrupts patients’ overall well-being and QOL. Furthermore, the HIV type-1 market growth may be offset by *failures and discontinuation of emerging therapies*, *unaffordable pricing*, *market access and reimbursement issues*, and a *shortage of healthcare specialists*. In addition, the *undiagnosed, unreported cases and the unawareness* about the disease may also impact the HIV type-1 market growth.

*HIV Type-1 Report Metrics* *Details*
Study Period 2019–2032
HIV Type-1 Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
HIV Type-1 Market Size in 2020  USD 22.6 Billion
Key HIV Type-1 Companies MacroGenics, CytoDyn, Inc., ViiV Healthcare, GlaxoSmithKline, PPD, Excision BioTherapeutics, TaiMed Biologics Inc., Gilead Sciences, ST Pharm Co., Ltd., Merck Sharp & Dohme LLC, Janssen Sciences Ireland UC, Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), AbbVie, Sanofi, ModeX Therapeutics, and others
Key HIV Type-1 Therapies MGD020, PRO 140, DTG/3TC, EBT-101, 18F-Raltegravir, TMB-365/TMB-380, Doravirine, GS-5894, STP0404, MK-8591A, Etravirine, VIR-1388, VH3739937, CVC, SAR441236, and others

*Scope of the **HIV Type-1** Market Report*

· *Therapeutic Assessment: *HIV Type-1 current marketed and emerging therapies
· *HIV Type-1* *Market Dynamics:* Attribute Analysis of Emerging HIV Type-1 Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, HIV Type-1 Market Access and Reimbursement*

Discover more about HIV type-1 drugs in development @ *HIV Type-1 Clinical Trials*

*Table of Contents*

1. HIV Type-1 Market Key Insights
2. HIV Type-1 Market Report Introduction
3. HIV Type-1 Market Overview at a Glance
4. HIV Type-1 Market Executive Summary
5. Disease Background and Overview
6. HIV Type-1 Treatment and Management
7. HIV Type-1 Epidemiology and Patient Population
8. Patient Journey
9. HIV Type-1 Marketed Drugs
10. HIV Type-1 Emerging Drugs
11. Seven Major HIV Type-1 Market Analysis
12. HIV Type-1 Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Related Reports*

*HIV Type-1 Epidemiology Forecast*

*HIV Type-1 Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted HIV type-1 epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

*HIV Type-1 Pipeline*

*HIV Type-1 Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HIV type-1 companies, including *United BioPharma, Gilead sciences, Taimed Biologics, Merck Sharp &Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics,  *among others.

*HIV-associated Lipodystrophy Market*

*HIV-associated Lipodystrophy Market Insights, Epidemiology, and Market Forecast – 2032* report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HIV-associated lipodystrophy companies, including *Gilead Sciences, Amgen, Abbott, AstraZeneca, AbbVie, GlaxoSmithKline, Alfa Wassermann SPA, Theratechnologies, Bristol-Myers Squibb, *among others.

*HIV-associated Lipodystrophy Epidemiology*

*HIV-associated Lipodystrophy Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted HIV-associated lipodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

*AIDS Market*

*AIDS Market Insights, Epidemiology, and Market Forecast **– 2032 *report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AIDS companies, including *Abbott, Gilead Sciences, Inc, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Mylan N.V, Johnson & Johnson Services, Inc, Merck & Co., Inc, Boehringer Ingelheim International GmbH, Cipla Inc, Hologic, Inc, Pfizer,* among others.

*Other Trending Reports*

*Digestive System Fistula Market** | **Dementia With Diabetes Market** | **Leber's Hereditary Optic Neuropathy Market** | **Pecoma Market** | **Adamantinoma Market** | **Pegfilgrastim Biosimilar Insight** | **Functional Constipation Market** | **DDR Defective Tumors Market** | **Nephrotic Syndrome Pipeline** | **Pelizaeus-Merzbacher Disease Market** | **Hepatic Impairment Market** | **Primary Ciliary Dyskinesia Market** | **Surgical Bleeding Market** | Radiotherapy-Induced** Oral Mucositis Market** | **Relapsed Chronic Lymphocytic Leukemia CLL Market** | **Galactosemia Market** | **Glabellar Lines Market** | **Homozygous Familial Hypercholesterolemia Market** | **HR Positive/ HER2 Negative Breast Cancer Market** | **Lebers Hereditary Optic Neuropathy LHON Market** | **Nonalcoholic Fatty Liver Disease NAFLD Market** | **Orthotic Devices Market** | **Polypoidal Choroidal Vasculopathy Market** | **Sporadic Inclusion Body Myositis Market** | **Acid Sphingomyelinase Deficiency ASMD Market** | **B-Cell Chronic Lymphocytic Leukemia Market** | **Coccidioidomycosis Market** | **Granulomatosis With Polyangiitis Market** | **Malignant Pleural Mesothelioma Market** | **Nocturnal Enuresis Market** | **Postmyocardial Infarction Syndrome Market** | **Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market** | **Typhoid Fever Market** | **Ventricular Dysfunction Market** | **Burkitt Lymphoma Market** | **Chronic Progressive Multiple Sclerosis Market** | **Emesis Market** | **Fenebrutinib Market** | **Gastric Neuroendocrine Tumors Market** | **Juvenile Rheumatoid Arthritis Market** | **Persistent Epithelial Defects Market** | **Post-Polycythemia Vera Myelofibrosis Market** | **Primary Mediastinal Large B-Cell Lymphoma Market** | **Spinocerebellar Ataxias Market** | **Systemic Inflammatory Response Syndrome Market** | **Triple Negative Breast Cancer Market** | **Visceral Pain Associated With GI Disorders Market** | **Adrenal Cortex Neoplasms Market** | **Adrenal Insufficiency Market** | **Artificial Lung Devices Market** | **Atopic Keratoconjunctivitis AKC Market** | **Autonomic Dysfunction Market** | **Bradycardia Treatment Devices Market** | **Bullous Pemphigoid Market** | **Cone Rod Dystrophy Market** | **Cutaneous Lupus Erythematosus Market** | **Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market** | **Dermal Regeneration Matrix Market** | **Heart Pump Devices Market** | **Hemiplegia Market** | **Hepatic Impairement Market** | **Immunologic Deficiency Syndrome Market** | **Implantable Infusion Pump Market** | **Menorrhalgia Market Size** | **Myocarditis Market** | **Myopia Treatment Devices Market** | **Ocular Hypertension Market *

*Related Healthcare Services*

*Healthcare Consulting*

*Healthcare Competitive Intelligence Services*

*Healthcare Asset Prioritization Services*

*About DelveInsight*

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*

*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com